PMDD Treatment with Serotonin Reuptake Inhibitors: Neuroactive Steroids and GABA May Play a Role
A new study from Miller and colleagues asks whether SRI treatment affects the levels of neuroactive steroids that act at GABA-A receptors.
A new study from Miller and colleagues asks whether SRI treatment affects the levels of neuroactive steroids that act at GABA-A receptors.
Childbirth-related PTSD is relatively common; routine screening with a survey of PTSD symptoms may identify women in need of specific PTSD interventions.
Every week we review the most recent publications in women’s mental health.
There are many different sources of information, some better than others.
The FDA approves zuranolone, a new option for the treatment of PPD, a rapidly acting antidepressant with a good safety profile.
In this multicenter cohort, maternal cannabis use documented using urine drug sampling was associated with increased risk of adverse pregnancy outcomes related to placental dysfunction.
Machine learning can be used to analyze data contained within the electronic health record to accurately predict which individuals are at increased risk for postpartum depression.
Dr. Lee S. Cohen, Director of the Ammon-Pinizzotto Center for Women's Mental Health at Massachusetts General Hospital, recently shared his insights on zuranolone for postpartum depression with Ob.Gyn News on December 14, 2023.
A wide range of delivery options may be effective for addressing symptoms of depression in perinatal individuals, and could therefore be leveraged to expand access to treatments.
A routinely administered single-item measure of sleep disturbance could identify pregnant individuals who are at risk for PPD and may benefit from depression prevention efforts.